Advertisement
Research Article Free access | 10.1172/JCI113647
Department of Medicine/Endocrinology, University of Texas Health Science Center, San Antonio 78284.
Find articles by Pfeilschifter, J. in: JCI | PubMed | Google Scholar
Department of Medicine/Endocrinology, University of Texas Health Science Center, San Antonio 78284.
Find articles by Seyedin, S. in: JCI | PubMed | Google Scholar
Department of Medicine/Endocrinology, University of Texas Health Science Center, San Antonio 78284.
Find articles by Mundy, G. in: JCI | PubMed | Google Scholar
Published August 1, 1988 - More info
TGF-beta 1 is a polypeptide that is abundant in bone matrix, is produced by bone cells, and modulates proliferation and differentiated functions of osteoblastic cells in vitro. TGF-beta 2 is a closely related polypeptide that was originally isolated from bone matrix. TGF-beta 1 has been shown previously to stimulate prostaglandin production in cultures of neonatal mouse calvariae, which causes these bones to resorb. We found similar effects with TGF-beta 2. In comparison, TGF-beta 1 and TGF-beta 2 failed to stimulate bone resorption in fetal rat long bone cultures during a 3-d incubation period in concentrations up to 50-100 times greater than those capable of inducing bone resorption in calvariae. Incubation with TGF-beta 1 for a further 3 d decreased bone resorption up to 30%. Moreover, bone resorption induced by the bone-resorbing agents IL 1 and 1,25-dihydroxyvitamin D3 was partially or completely inhibited by TGF-beta 1 and TGF-beta 2 during the second half of the 6-d incubation period. Inhibition of DNA synthesis with hydroxyurea inhibited bone resorption in long bones in a similar pattern to that seen with TGF-beta 1. The inhibitory effects of TGF-beta 1 and TGF-beta 2 on bone resorption in long bone cultures may therefore be due to inhibition of osteoclast precursor proliferation.